Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen

被引：36

作者：

Harris, Marianne ^{[1
]}

Larsen, Gerene ^{[1
]}

Montaner, Julio S. G. ^{[1
,2
]}

机构：

[1] St Pauls Hosp, AIDS Res Program, Vancouver, BC V6Z 1Y6, Canada

[2] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada

来源：

AIDS | 2008年 / 22卷 / 10期

关键词：

D O I：

10.1097/QAD.0b013e328302f3b5

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Enfuvirtide has been a cornerstone of salvage therapy for multidrug-resistant HIV. Raltegravir provides another novel class option, with the advantages of easier administration and improved tolerability. Thirty-five adults electively replaced enfuvirtide with raltegravir while the rest of their regimen was unchanged. All maintained virologic suppression after a median of 7 months except one who experienced a transiently detectable viral load after 5 months. The new regimen was well tolerated with no apparent new drug-related adverse clinical or laboratory events.

引用

页码：1224 / 1226

页数：3

共 7 条

[1]

COOPER D, 2008, 15 C RETR OPP INF BO

[2] Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial [J].

Grinsztejn, Beatriz ;

Nguyen, Bach-Yen ;

Katlama, Christine ;

Gatell, Jose M. ;

Lazzarin, Adriano ;

Vittecoq, Daniel ;

Gonzalez, Charles J. ;

Chen, Joshua ;

Harvey, Charlotte M. ;

Isaacs, Robin D. .

LANCET, 2007, 369 (9569) :1261-1269

[3] Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America [J].

Lalezari, JP ;

Henry, K ;

O'Hearn, M ;

Montaner, JSG ;

Piliero, PJ ;

Trottier, B ;

Walmsley, S ;

Cohen, C ;

Kuritzkes, DR ;

Eron, JJ ;

Chung, J ;

DeMasi, R ;

Donatacci, L ;

Drobnes, C ;

Delehanty, J ;

Salgo, M ;

Farthing, C ;

Graham, E ;

Packard, M ;

Ngo, L ;

Lederman, M ;

Buam, J ;

Pollard, R ;

Rauf, S ;

Silkowski, W ;

Thompson, M ;

Rucker, A ;

Harris, M ;

Larsen, G ;

Preseon, S ;

Cunningham, D ;

Guimaraes, D ;

Bertasso, A ;

Kinchelow, T ;

Myers, R ;

Phoenix, BCBP ;

Skolnik, PR ;

Adams, B ;

Leite, OHM ;

Oliveira, M ;

Lefebvre, E ;

Gomez, B ;

Foy, KB ;

Lampiris, H ;

Charles, S ;

Dobkin, J ;

Crawford, M ;

Slom, T ;

Murphy, R ;

Mikaitis, T .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (22) :2175-2185

[4] Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia [J].

Lazzarin, A ;

Clotet, B ;

Cooper, D ;

Reynes, J ;

Arasteh, K ;

Nelson, M ;

Katlama, C ;

Stellbrink, H ;

Delfraissy, J ;

Lange, J ;

Huson, L ;

DeMasi, R ;

Wat, C ;

Delehanty, J ;

Drobnes, C ;

Salgo, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (22) :2186-2195

[5]

STEIGBIGEL R, 2008, 15 C RETR OPP INF BO

[6] Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks [J].

Trottier, B ;

Walmsley, S ;

Reynes, J ;

Piliero, P ;

O'Hearn, M ;

Nelson, M ;

Montaner, J ;

Lazzarin, A ;

Lalezari, J ;

Katlama, C ;

Henry, K ;

Cooper, D ;

Clotet, B ;

Arastéh, K ;

Delfraissy, JF ;

Stellbrink, HJ ;

Lange, J ;

Kuritzkes, D ;

Eron, JJ ;

Cohen, C ;

Kinchelow, T ;

Bertasso, A ;

Labriola-Tompkins, E ;

Shikhman, A ;

Atkins, B ;

Bourdeau, L ;

Natale, C ;

Hughes, F ;

Chung, J ;

Guimaraes, D ;

Drobnes, C ;

Bader-Weder, S ;

DeMasi, R ;

Smiley, L ;

Salgo, MP .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 40 (04) :413-421

[7]

WENNING LA, 2006, 46 ANN INT C ANT AG

← 1 →